Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

Medicare to Negotiate Prices for 15 More Drugs, Including Ozempic By India Edwards HealthDay Reporter WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- Medicare will soon negotiate prices for 15 more ...

See the 10 stocks » However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and ...